Check Availability & Expiry
INTRODUCTION
IMATIB contains Imatinib mesylate which belongs to a group of medicines called corticosteroids which reduces inflammation. It is indicated to treat chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia in adults and children.
Leukaemia is a cancer of white blood cells, the cells usually help the body to fight infection. IMATIB also used to treat myelodysplastic/myeloproliferative diseases, hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia, gastrointestinal stromal tumours and dermatofibrosarcoma protuberans in adults. Tyrosine kinases are proteins which act as chemical messengers that are used by the cancer cells to signal to each other for their growth. This medicine works by blocking this enzyme and stops the cancer cells from growing.
Take this medicine according to the dose and frequency as advised by your doctor. Swallow whole with a large glass of water. It can be taken with food. The common side effects are fluid retention, weight gain. Before taking this medicine tell your doctor if you have kidney, liver or heart problems. It is not recommended during pregnancy and breastfeeding.
USES OF IMATIB
- Chronic myeloid leukaemia
- Philadelphia chromosome positive acute lymphoblastic leukaemia
- Myelodysplastic/myeloproliferative diseases
- Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia
- Gastrointestinal stromal tumours
- Dermatofibrosarcoma protuberans
HOW IMATIB WORKS
IMATIB is a protein-tyrosine kinase inhibitor. Tyrosine kinases are proteins which act as chemical messengers that are used by the cancer cells to signal to each other for their growth. Imatinib mesylate by blocking this enzyme stops the cancer cells from growing.
DIRECTIONS FOR USE
Take this medicine according to the dose and frequency as advised by your doctor. Swallow whole with a large glass of water. It can be taken with food.
SIDE EFFECTS OF IMATIB
COMMON
- rapid weight gain (severe fluid retention)
- fever, severe chills
- sore throat
- mouth ulcers
- unexpected bleeding or bruising
WARNING & PRECAUTIONS
PREGNANCY
IMATIB is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor.
BREASTFEEDING
IMATIB is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor.
DRIVING AND USING MACHINES
Do not drive or operate machinery while taking this medicine, since it may cause dizziness, drowsiness or blurred vision.
KIDNEY
IMATIB should be used with caution in patients suffering from active kidney diseases. Consult your doctor for advice.
LIVER
IMATIB should be used with caution in patients suffering from liver function impairment or active liver diseases. Consult your doctor for advice.
ALLERGY
Do not take if you are allergic (hypersensitive) to Imatinib.
HEART DISEASE
IMATIB should be used with caution in patients suffering from active heart diseases. Consult your doctor for advice.
OTHERS
Inform your doctor if you have,
- hepatitis B infection
INTERACTIONS
Inform your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or the following,
- levothyroxine
- paracetamol
- herbal medicines (St. John’s Wort)
- medicines used to prevent the formation of blood clots
SYNOPSIS
| Drug | : | Imatinib |
| Pharmacological Category | : | Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor |
| Therapeutic Indication | : | Leukemia, Gastrointestinal stromal tumors |
| Dosage Forms | : | Tablet |
MORE INFORMATION
Store below 20-25°C and keep out of reach of children.
FAQs ABOUT IMATIB
Can use IMATIB during pregnancy?
This medicine is not recommended during pregnancy, or if you are planning to get pregnant.
Does IMATIB safe while driving?
Do not drive or operate any machines since it may cause dizziness, drowsiness or blurred vision
What causes chronic myeloid leukaemia?
It is caused by a genetic change in the stem cells produced by the bone marrow which causes the stem cells to produce too many underdeveloped white blood cells.
REFERENCES
1. KD Tripathi MD. Chemotherapy of neoplastic diseases: Anticancer Drugs. Essentials of Medical Pharmacology 7th ed. New Delhi, May 2013. Page – 869.
2. Chabner BA, Barnes J, Neal. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. Page: 1732-1734.
3. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page: 692-694.
4. Nida Iqbal & Naveed Iqbal. Imatinib: A Breakthrough of Targeted Therapy in Cancer; May 19, 2014 [Accessed Nov 6 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055302/
5. Novartis Limited, 7 Nov 2001; [Revised 7 Nov 2006] [Accessed Nov 6, 2020] https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf
6. Novartis Pharmaceuticals Corporation; U.S. Food & Drug Administration [Accessed Nov 6, 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s009lbl.pdf
USEFUL DIAGNOSTIC TESTS
- Bcr-Abl Gene Translocation
- Bcr-Abl Gene Translocation
- Complete Blood Count
- Peripheral Smear Examination
PRODUCT DETAILS
ALTERNATE BRANDS View All
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.
